Encorafenib in combination with binimetinib in second line palliative treatment in 44-year patient with symptoms of spinal cord compression
Abstract
The described case concerns a 44-year-old patient with metastatic skin melanoma and the presence of BRAF
mutation, who was treated with combined immunotherapy (nivolumab and ipilimumab) with the result of hyperprogression.
The first signs of spinal cord compression were observed before the treatment with encorafenib and
binimetinib was started. Despite a poor prognosis related to fast progression, the presence of CNS metastases
and the presence of BRAF mutations, the treatment allowed for a good control of the symptoms of the disease
for about six months and improved the quality of patient’s life. The combination of BRAF/MEK inhibitors was well
tolerated and there was no need for a dose reduction.
Keywords: advanced melanomaBRAF mutationencorafenibbinimetinibbrain metastases
References
- Rutkowski P, Wysocki P, Kozak K, et al. Expert recommendations on diagnostic-therapeutic management of melanoma patients. Oncol Clin Pract. 2022; 18(6): 357–392.
- Rutkowski P, Kiprian D, Dudzisz-Śledź M, et al. Management of brain metastases in melanoma. Oncol Clin Pract. 2019; 15.
- Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5): 603–615.
- Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018; 19(10): 1315–1327.
- Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017; 23(8): 1920–1928.
- Popat V, Gerber DE. Hyperprogressive disease: a distinct effect of immunotherapy? J Thorac Dis. 2019; 11(Suppl 3): S262–S265.
- Pałucki J, Kucharz J. Ocena odpowiedzi w immunoterapii nowotworów. Współpraca onkolog-radiolog. Oncol Clin Pract. 2022; 18(2): 119–127.